1. Home
  2. BXC vs KMDA Comparison

BXC vs KMDA Comparison

Compare BXC & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bluelinx Holdings Inc.

BXC

Bluelinx Holdings Inc.

N/A

Current Price

$51.80

Market Cap

587.2M

ML Signal

N/A

Logo Kamada Ltd.

KMDA

Kamada Ltd.

N/A

Current Price

$8.11

Market Cap

501.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BXC
KMDA
Founded
2004
1990
Country
United States
Israel
Employees
1700
N/A
Industry
Wholesale Distributors
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
587.2M
501.8M
IPO Year
2004
2013

Fundamental Metrics

Financial Performance
Metric
BXC
KMDA
Price
$51.80
$8.11
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
2
Target Price
$86.00
$14.00
AVG Volume (30 Days)
84.6K
70.4K
Earning Date
04-28-2026
03-11-2026
Dividend Yield
N/A
2.94%
EPS Growth
N/A
N/A
EPS
0.02
N/A
Revenue
N/A
N/A
Revenue This Year
$5.04
$14.04
Revenue Next Year
$5.09
$7.99
P/E Ratio
$2,261.00
$24.59
Revenue Growth
N/A
N/A
52 Week Low
$44.78
$5.54
52 Week High
$88.30
$9.35

Technical Indicators

Market Signals
Indicator
BXC
KMDA
Relative Strength Index (RSI) 37.32 38.54
Support Level N/A $6.70
Resistance Level $74.08 $8.30
Average True Range (ATR) 2.79 0.26
MACD -0.32 -0.11
Stochastic Oscillator 34.42 4.55

Price Performance

Historical Comparison
BXC
KMDA

About BXC Bluelinx Holdings Inc.

BlueLinx Holdings Inc is engaged in the wholesale distribution of residential and commercial building products. Its business products are split into two categories: Structural products include items such as lumber, plywood, oriented strand board, rebar, and remesh and Specialty products include items such as engineered wood, siding, millwork, outdoor living, specialty lumber and panels, and industrial products. The company's operations are carried out throughout the United States.

About KMDA Kamada Ltd.

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

Share on Social Networks: